ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,703,505 | +12.6% | 225,696 | +29.4% | 0.01% | +20.0% |
| Q2 2023 | $4,177,431 | +89.8% | 174,423 | +49.2% | 0.01% | +66.7% |
| Q1 2023 | $2,200,453 | +33.8% | 116,921 | +13.2% | 0.00% | +50.0% |
| Q4 2022 | $1,644,870 | -19.5% | 103,321 | -18.4% | 0.00% | -33.3% |
| Q3 2022 | $2,044,000 | +30.3% | 126,660 | +13.7% | 0.00% | +50.0% |
| Q2 2022 | $1,569,000 | -32.5% | 111,360 | +16.0% | 0.00% | 0.0% |
| Q1 2022 | $2,324,000 | -27.2% | 95,960 | -29.9% | 0.00% | -33.3% |
| Q4 2021 | $3,194,000 | +53.8% | 136,842 | +9.4% | 0.00% | +50.0% |
| Q3 2021 | $2,077,000 | -30.3% | 125,051 | -9.2% | 0.00% | -33.3% |
| Q2 2021 | $2,980,000 | -17.2% | 137,751 | -1.3% | 0.00% | -25.0% |
| Q1 2021 | $3,600,000 | -63.2% | 139,517 | -23.8% | 0.00% | -66.7% |
| Q4 2020 | $9,792,000 | -2.1% | 183,173 | -24.4% | 0.01% | -14.3% |
| Q3 2020 | $9,998,000 | -19.3% | 242,373 | -5.1% | 0.01% | -22.2% |
| Q2 2020 | $12,383,000 | +19.5% | 255,473 | +4.2% | 0.02% | 0.0% |
| Q1 2020 | $10,359,000 | -14.5% | 245,176 | -13.4% | 0.02% | 0.0% |
| Q4 2019 | $12,112,000 | +61.9% | 283,119 | +36.2% | 0.02% | +63.6% |
| Q3 2019 | $7,483,000 | +69.2% | 207,905 | +25.7% | 0.01% | +57.1% |
| Q2 2019 | $4,422,000 | +3.1% | 165,449 | +3.6% | 0.01% | 0.0% |
| Q1 2019 | $4,289,000 | +80.1% | 159,749 | +8.5% | 0.01% | +75.0% |
| Q4 2018 | $2,381,000 | +6.6% | 147,249 | +36.8% | 0.00% | +33.3% |
| Q3 2018 | $2,234,000 | +81.0% | 107,600 | +228.4% | 0.00% | +50.0% |
| Q3 2017 | $1,234,000 | -28.9% | 32,761 | -47.4% | 0.00% | -33.3% |
| Q2 2017 | $1,736,000 | -41.1% | 62,261 | -27.3% | 0.00% | -40.0% |
| Q1 2017 | $2,945,000 | -10.7% | 85,661 | -25.1% | 0.01% | -16.7% |
| Q4 2016 | $3,299,000 | -26.8% | 114,387 | -19.3% | 0.01% | -25.0% |
| Q3 2016 | $4,507,000 | -8.0% | 141,687 | -6.2% | 0.01% | -11.1% |
| Q2 2016 | $4,901,000 | -1.2% | 151,000 | -14.9% | 0.01% | 0.0% |
| Q1 2016 | $4,960,000 | +6.6% | 177,400 | +35.9% | 0.01% | 0.0% |
| Q4 2015 | $4,652,000 | +4.3% | 130,500 | -3.3% | 0.01% | 0.0% |
| Q3 2015 | $4,461,000 | -17.4% | 134,900 | +4.7% | 0.01% | -10.0% |
| Q2 2015 | $5,398,000 | +25.7% | 128,900 | -2.2% | 0.01% | +25.0% |
| Q1 2015 | $4,295,000 | +14.5% | 131,800 | +11.6% | 0.01% | +33.3% |
| Q4 2014 | $3,750,000 | +31.6% | 118,100 | +2.6% | 0.01% | +20.0% |
| Q3 2014 | $2,850,000 | +17.8% | 115,100 | +7.5% | 0.01% | +25.0% |
| Q2 2014 | $2,419,000 | +141.4% | 107,100 | +160.0% | 0.00% | +100.0% |
| Q1 2014 | $1,002,000 | +5.8% | 41,200 | +8.7% | 0.00% | 0.0% |
| Q4 2013 | $947,000 | +5.5% | 37,900 | +15.9% | 0.00% | 0.0% |
| Q3 2013 | $898,000 | +71.0% | 32,700 | +13.1% | 0.00% | +100.0% |
| Q2 2013 | $525,000 | – | 28,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |